Search

CX-052075

CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1 … [L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586]

Betibeglogene autotemcel

donor due to the risks of graft rejection, graft-versus-host disease, and other treatment-related toxic effects. … [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin.

Letaxaban

Letaxaban has been used in trials studying the treatment and prevention of Venous Thromboembolism and Acute Coronary Syndrome.

MBO7133

Higher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue. … MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver.

MVA-SARS-2-S

MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines … MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein[L30453].

GW-813893

PF-03187207

PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

Rivanicline

Rivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release. … It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis.

AIT-034

AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do … There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia.

Sacituzumab govitecan

As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.